Symbols / ALVO Stock $4.22 +1.93% Alvotech

Healthcare • Drug Manufacturers - Specialty & Generic • Luxembourg • NGM
ALVO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Ms. Lisa Graver
Exch · Country NGM · Luxembourg
Market Cap 1.32B
Enterprise Value 2.69B
Income -80.73M
Sales 562.04M
FCF (ttm) -92.55M
Book/sh -0.91
Cash/sh 0.20
Employees 1,279
Insider 10d —
IPO Jun 16, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 23.58
PEG —
P/S 2.34
P/B -4.66
P/C —
EV/EBITDA 25.77
EV/Sales 4.78
Quick Ratio 0.67
Current Ratio 1.75
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.29
EPS next Y 0.18
EPS Growth -99.00%
Revenue Growth -20.20%
EPS Gr Q/Q -99.10%
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-05-06
ROA 3.84%
ROE —
ROIC —
Gross Margin 61.53%
Oper. Margin 9.13%
Profit Margin -14.36%
Shs Outstand 312.15M
Shs Float 114.14M
Insider Own 62.73%
Instit Own 6.45%
Short Float 2.53%
Short Ratio 6.99
Short Interest 2.93M
52W High 10.07
vs 52W High -58.09%
52W Low 2.94
vs 52W Low 43.54%
Beta 0.21
Impl. Vol. —
Rel Volume 1.57
Avg Volume 571.25K
Volume 896.65K
Target (mean) $13.83
Tgt Median $7.50
Tgt Low $4.00
Tgt High $50.00
# Analysts 6
Recom Buy
Prev Close $4.14
Price $4.22
Change 1.93%
About

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$13.83
Mean price target
2. Current target
$4.22
Latest analyst target
3. DCF / Fair value
$-5.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.22
Low
$4.00
High
$50.00
Mean
$13.83

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-24 main UBS Buy → Buy $6
2026-03-24 main Barclays Underweight → Underweight $4
2025-12-09 init Barclays — → Underweight $5
2025-11-18 main UBS Buy → Buy $10
2025-11-04 down Deutsche Bank Buy → Hold $8
2025-10-14 up Morgan Stanley Equal-Weight → Overweight $14
2025-09-23 up Deutsche Bank Hold → Buy $14
2025-07-18 main UBS Buy → Buy $14
2025-02-14 init UBS — → Buy $18
2024-07-25 main Barclays Overweight → Overweight $18
2024-05-24 main Barclays Overweight → Overweight $22
2024-03-22 main Barclays Overweight → Overweight $20
2024-01-29 up Barclays Equal-Weight → Overweight $17
2023-10-20 up Citigroup Sell → Neutral $10
2023-09-21 init Barclays — → Equal-Weight $10
2023-03-07 main Deutsche Bank — → Hold $12
2022-09-07 init Morgan Stanley — → Equal-Weight $10
2022-09-06 down Citigroup Buy → Sell $5
2022-07-26 init Citigroup — → Buy $12
2022-07-01 init Deutsche Bank — → Hold $10
News
RSS: Latest ALVO news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
586.32
+19.74%
489.68
+435.56%
91.43
+10.12%
83.03
Operating Revenue
586.32
+19.74%
489.68
+435.56%
91.43
+10.12%
83.03
Cost Of Revenue
235.56
+27.12%
185.31
+15.20%
160.86
+150.96%
64.09
Reconciled Cost Of Revenue
203.74
+28.73%
158.27
+12.91%
140.17
+197.97%
47.04
Gross Profit
350.76
+15.24%
304.37
+538.44%
-69.42
-466.65%
18.93
Operating Expense
272.56
+16.12%
234.73
-17.77%
285.44
-21.88%
365.38
Research And Development
184.19
+7.52%
171.31
-18.74%
210.83
+16.72%
180.62
Selling General And Administration
84.92
+38.18%
61.45
-15.86%
73.04
-60.17%
183.39
General And Administrative Expense
84.92
+38.18%
61.45
-15.86%
73.04
-60.17%
183.39
Salaries And Wages
39.56
+1.09%
39.13
-10.37%
43.66
+9.22%
39.98
Other Gand A
45.36
+103.20%
22.32
-24.02%
29.38
-79.52%
143.41
Other Operating Expenses
-2.58
-12.50%
-2.30
-17.86%
-1.95
+2.01%
-1.99
Total Expenses
508.11
+20.97%
420.04
-5.88%
446.29
+3.92%
429.47
Operating Income
78.21
+12.30%
69.64
+119.63%
-354.86
-2.43%
-346.44
Total Operating Income As Reported
78.21
+12.30%
69.64
+119.63%
-354.86
-2.43%
-346.44
EBITDA
311.07
+1063.81%
-32.27
+93.46%
-493.67
-8.79%
-453.76
Normalized EBITDA
109.61
+7.52%
101.95
+130.47%
-334.64
+2.06%
-341.68
Reconciled Depreciation
37.85
+20.93%
31.30
+29.29%
24.21
+18.62%
20.41
EBIT
273.22
+529.75%
-63.58
+87.72%
-517.88
-9.22%
-474.17
Total Unusual Items
201.45
+250.09%
-134.22
+15.60%
-159.03
-41.88%
-112.09
Total Unusual Items Excluding Goodwill
201.45
+250.09%
-134.22
+15.60%
-159.03
-41.88%
-112.09
Special Income Charges
26.45
+136.55%
-72.35
-236.21%
-21.52
+21.21%
-27.31
Other Special Charges
-18.47
-126.62%
69.38
—
27.31
Restructuring And Mergern Acquisition
-7.98
0.00
—
—
Write Off
0.00
0.00
-100.00%
21.52
0.00
Net Income
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Pretax Income
136.35
+162.67%
-217.56
+66.58%
-651.05
-18.02%
-551.65
Net Non Operating Interest Income Expense
-143.31
+6.32%
-152.98
-17.68%
-130.00
-43.61%
-90.53
Interest Expense Non Operating
136.87
-11.12%
153.99
+15.63%
133.17
+71.89%
77.47
Net Interest Income
-143.31
+6.32%
-152.98
-17.68%
-130.00
-43.61%
-90.53
Interest Expense
136.87
-11.12%
153.99
+15.63%
133.17
+71.89%
77.47
Interest Income Non Operating
2.77
-40.11%
4.62
-4.27%
4.82
+428.84%
0.91
Interest Income
2.77
-40.11%
4.62
-4.27%
4.82
+428.84%
0.91
Other Income Expense
201.45
+250.09%
-134.22
+19.23%
-166.19
-44.92%
-114.68
Gain On Sale Of Security
175.01
+382.84%
-61.88
+55.01%
-137.52
-62.21%
-84.78
Gain On Sale Of Business
0.00
+100.00%
-2.97
0.00
0.00
Tax Provision
108.43
+658.19%
14.30
+114.40%
-99.32
-160.90%
-38.07
Tax Rate For Calcs
0.00
+0.00%
0.00
+37.25%
0.00
+121.74%
0.00
Tax Effect Of Unusual Items
42.31
+250.09%
-28.19
-15.84%
-24.33
-214.61%
-7.73
Net Income Including Noncontrolling Interests
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Net Income From Continuing Operation Net Minority Interest
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Net Income From Continuing And Discontinued Operation
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Net Income Continuous Operations
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Normalized Income
-131.23
-4.29%
-125.83
+69.83%
-417.03
-1.91%
-409.23
Net Income Common Stockholders
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Diluted EPS
0.10
+111.49%
-0.87
+64.20%
-2.43
+6.54%
-2.60
Basic EPS
0.10
+111.49%
-0.87
+64.20%
-2.43
+6.54%
-2.60
Basic Average Shares
279.19
+4.76%
266.51
+17.27%
227.26
+15.05%
197.53
Diluted Average Shares
279.19
+4.76%
266.51
-0.53%
267.92
+35.64%
197.53
Diluted NI Availto Com Stockholders
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Depreciation Amortization Depletion Income Statement
6.03
+41.54%
4.26
+20.96%
3.52
+4.98%
3.35
Depreciation And Amortization In Income Statement
6.03
+41.54%
4.26
+20.96%
3.52
+4.98%
3.35
Earnings From Equity Interest
0.00
0.00
+100.00%
-7.15
-176.18%
-2.59
Total Other Finance Cost
9.21
+154.79%
3.61
+118.11%
1.66
-88.13%
13.96
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
1,487.10
+21.75%
1,221.40
+28.56%
950.09
Current Assets
574.01
+26.15%
455.02
+133.53%
194.84
Cash Cash Equivalents And Short Term Investments
172.36
+235.15%
51.43
+360.95%
11.16
Cash And Cash Equivalents
172.36
+235.15%
51.43
+360.95%
11.16
Receivables
153.79
-38.91%
251.72
+188.61%
87.22
Accounts Receivable
69.74
-56.47%
160.22
+288.01%
41.29
Other Receivables
65.68
-10.83%
73.67
+103.34%
36.23
Taxes Receivable
17.92
+1.16%
17.72
+101.33%
8.80
Inventory
220.05
+72.07%
127.89
+71.82%
74.43
Raw Materials
102.16
+90.71%
53.57
+3.96%
51.52
Work In Process
124.33
+53.03%
81.24
+145.68%
33.07
Finished Goods
1.38
0.00
-100.00%
0.24
Prepaid Assets
27.82
+15.98%
23.98
+8.85%
22.04
Hedging Assets Current
—
—
0.00
Total Non Current Assets
913.08
+19.14%
766.38
+1.47%
755.25
Net PPE
494.69
+20.73%
409.74
+14.91%
356.58
Gross PPE
599.21
+21.21%
494.36
+16.40%
424.71
Accumulated Depreciation
-104.52
-23.52%
-84.61
-24.20%
-68.13
Machinery Furniture Equipment
592.66
+21.61%
487.36
+17.16%
415.99
Other Properties
6.55
-6.42%
7.00
-19.75%
8.72
Goodwill And Other Intangible Assets
94.67
+196.29%
31.95
+2.62%
31.13
Goodwill
12.84
+13.28%
11.33
-6.04%
12.06
Other Intangible Assets
81.83
+296.85%
20.62
+8.10%
19.08
Investments And Advances
—
0.00
-100.00%
18.49
Long Term Equity Investment
—
0.00
-100.00%
18.49
Non Current Accounts Receivable
122.93
+441.32%
22.71
+109.19%
10.86
Non Current Deferred Assets
192.21
-35.58%
298.36
-3.69%
309.81
Non Current Deferred Taxes Assets
192.21
-35.58%
298.36
-3.69%
309.81
Other Non Current Assets
8.58
+137.29%
3.62
-87.26%
28.38
Total Liabilities Net Minority Interest
1,771.59
+8.41%
1,634.17
-13.20%
1,882.58
Current Liabilities
304.08
+57.23%
193.40
-25.89%
260.95
Payables And Accrued Expenses
215.38
+67.52%
128.57
-12.73%
147.32
Payables
130.49
+72.16%
75.80
-17.02%
91.34
Accounts Payable
126.12
+87.89%
67.13
-16.68%
80.56
Other Payable
—
—
—
Current Accrued Expenses
84.89
+60.85%
52.77
-5.74%
55.99
Employee Benefits
—
—
0.00
Pensionand Other Post Retirement Benefit Plans Current
9.34
+40.81%
6.63
-1.53%
6.73
Total Tax Payable
1.04
+410.29%
0.20
-77.95%
0.93
Current Debt And Capital Lease Obligation
49.00
+16.06%
42.22
-11.51%
47.71
Current Debt
36.92
+12.90%
32.70
-14.00%
38.02
Other Current Borrowings
36.92
+12.90%
32.70
-14.00%
38.02
Current Capital Lease Obligation
12.08
+26.94%
9.52
-1.73%
9.68
Current Deferred Liabilities
30.36
+90.01%
15.98
-73.00%
59.18
Current Deferred Revenue
30.36
+90.01%
15.98
-73.00%
59.18
Total Non Current Liabilities Net Minority Interest
1,467.51
+1.86%
1,440.78
-11.15%
1,621.63
Long Term Debt And Capital Lease Obligation
1,400.15
+21.96%
1,148.02
+11.70%
1,027.77
Long Term Debt
1,262.15
+21.84%
1,035.88
+12.34%
922.13
Long Term Capital Lease Obligation
138.00
+23.06%
112.14
+6.16%
105.63
Tradeand Other Payables Non Current
—
—
0.00
Non Current Deferred Liabilities
13.37
-83.80%
82.53
+12.57%
73.31
Non Current Deferred Revenue
5.50
-93.19%
80.72
+10.18%
73.26
Non Current Deferred Taxes Liabilities
7.87
+334.46%
1.81
+3316.98%
0.05
Stockholders Equity
-284.49
+31.08%
-412.77
+55.73%
-932.49
Common Stock Equity
-284.49
+31.08%
-412.77
+55.73%
-932.49
Capital Stock
2.93
+3.64%
2.83
+24.00%
2.28
Common Stock
2.93
+3.64%
2.83
+24.00%
2.28
Share Issued
334.04
+2.84%
324.80
+12.11%
289.73
Ordinary Shares Number
312.02
+3.38%
301.81
+13.11%
266.82
Treasury Shares Number
22.02
-4.26%
23.00
+0.39%
22.91
Additional Paid In Capital
2,105.69
+4.91%
2,007.06
+63.22%
1,229.69
Retained Earnings
-2,409.79
+1.15%
-2,437.71
-10.51%
-2,205.84
Gains Losses Not Affecting Retained Earnings
16.68
+10.82%
15.05
-63.62%
41.38
Other Equity Adjustments
15.33
-11.24%
17.27
-59.75%
42.91
Total Equity Gross Minority Interest
-284.49
+31.08%
-412.77
+55.73%
-932.49
Total Capitalization
977.66
+56.90%
623.11
+6115.17%
-10.36
Working Capital
269.94
+3.18%
261.62
+495.75%
-66.11
Invested Capital
1,014.58
+54.71%
655.81
+2270.47%
27.67
Total Debt
1,449.14
+21.75%
1,190.24
+10.67%
1,075.47
Net Debt
1,126.71
+10.77%
1,017.16
+7.18%
949.00
Capital Lease Obligations
150.08
+23.37%
121.65
+5.50%
115.31
Net Tangible Assets
-379.16
+14.74%
-444.72
+53.85%
-963.63
Tangible Book Value
-379.16
+14.74%
-444.72
+53.85%
-963.63
Derivative Product Liabilities
53.99
-74.32%
210.22
-59.62%
520.55
Duefrom Related Parties Current
0.44
+271.19%
0.12
-86.83%
0.90
Dueto Related Parties Current
3.33
-60.72%
8.46
-14.07%
9.85
Dueto Related Parties Non Current
—
—
0.00
Foreign Currency Translation Adjustments
1.35
+160.96%
-2.22
-45.16%
-1.53
Interest Payable
19.86
+4540.19%
0.43
-87.16%
3.33
Inventories Adjustments Allowances
-7.82
-12.96%
-6.92
+33.48%
-10.40
Investmentsin Joint Venturesat Cost
—
0.00
-100.00%
18.49
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-50.20
+78.81%
-236.84
+24.13%
-312.19
+0.07%
-312.39
Cash Flow From Continuing Operating Activities
-50.20
+78.81%
-236.84
+24.13%
-312.19
+0.07%
-312.39
Net Income From Continuing Operations
27.92
+112.04%
-231.86
+57.98%
-551.73
-7.43%
-513.58
Depreciation Amortization Depletion
37.85
+20.93%
31.30
+29.29%
24.21
+18.62%
20.41
Depreciation And Amortization
37.85
+20.93%
31.30
+29.29%
24.21
+18.62%
20.41
Other Non Cash Items
-67.00
-122.92%
292.40
+11.43%
262.41
-13.13%
302.08
Stock Based Compensation
7.38
-3.25%
7.63
-57.71%
18.03
+74.79%
10.32
Provisionand Write Offof Assets
1.35
+130.46%
-4.43
-116.50%
26.84
0.00
Asset Impairment Charge
0.00
0.00
-100.00%
23.30
+745.66%
2.75
Deferred Tax
108.43
+658.19%
14.30
+114.40%
-99.32
-160.90%
-38.07
Deferred Income Tax
108.43
+658.19%
14.30
+114.40%
-99.32
-160.90%
-38.07
Operating Gains Losses
8.86
+270.76%
-5.19
-140.87%
12.70
+199.39%
-12.78
Gain Loss On Investment Securities
—
—
132.33
+38.80%
95.34
Net Foreign Currency Exchange Gain Loss
16.84
+306.36%
-8.16
-257.46%
5.18
+149.05%
-10.57
Gain Loss On Sale Of PPE
0.00
0.00
-100.00%
0.36
0.00
Change In Working Capital
-117.64
+59.24%
-288.64
-1196.34%
26.33
+154.98%
-47.89
Change In Receivables
-2.08
+98.73%
-164.24
-561.38%
-24.83
-87.68%
-13.23
Changes In Account Receivables
93.18
+178.26%
-119.06
-1331.05%
-8.32
-132.66%
-3.58
Change In Inventory
-90.13
-80.36%
-49.97
-342.08%
-11.30
+65.12%
-32.41
Change In Payables And Accrued Expense
45.31
+430.87%
-13.70
-143.10%
31.77
+93.24%
16.44
Change In Payable
45.31
+430.87%
-13.70
-143.10%
31.77
+93.24%
16.44
Change In Account Payable
—
—
—
—
Change In Other Working Capital
-69.33
-120.49%
-31.45
-188.84%
35.40
+82.49%
19.40
Change In Other Current Assets
-4.24
+40.44%
-7.12
-788.40%
-0.80
+95.34%
-17.19
Change In Other Current Liabilities
2.84
+112.81%
-22.17
-468.17%
-3.90
+81.32%
-20.89
Investing Cash Flow
-104.22
-452.34%
-18.87
+59.28%
-46.34
+27.07%
-63.54
Cash Flow From Continuing Investing Activities
-104.22
-452.34%
-18.87
+59.28%
-46.34
+27.07%
-63.54
Net PPE Purchase And Sale
-64.47
-20.14%
-53.66
-62.11%
-33.10
+11.73%
-37.50
Purchase Of PPE
-64.47
-20.14%
-53.66
-61.46%
-33.23
+12.27%
-37.88
Sale Of PPE
0.00
0.00
-100.00%
0.13
-64.91%
0.38
Capital Expenditure
-96.13
-68.65%
-57.00
-22.65%
-46.47
+5.16%
-49.00
Net Business Purchase And Sale
-8.09
-167.38%
12.00
0.00
0.00
Purchase Of Business
-14.04
0.00
0.00
—
Gain Loss On Sale Of Business
0.00
-100.00%
2.97
0.00
0.00
Net Intangibles Purchase And Sale
-31.66
-848.16%
-3.34
+74.78%
-13.24
-19.03%
-11.12
Purchase Of Intangibles
-31.66
-848.16%
-3.34
+74.78%
-13.24
-19.03%
-11.12
Net Other Investing Changes
—
26.13
—
-14.91
Financing Cash Flow
270.83
-8.90%
297.31
-1.33%
301.32
-29.09%
424.91
Cash Flow From Continuing Financing Activities
270.83
-8.90%
297.31
-1.33%
301.32
-29.09%
424.91
Net Issuance Payments Of Debt
197.69
+30.08%
151.98
-11.22%
171.19
-33.60%
257.82
Issuance Of Debt
233.48
-74.64%
920.76
+230.22%
278.83
-21.16%
353.68
Repayment Of Debt
-35.79
+95.34%
-768.78
-614.24%
-107.64
-12.28%
-95.86
Long Term Debt Issuance
233.48
-74.64%
920.76
+230.22%
278.83
-21.16%
353.68
Long Term Debt Payments
-35.79
+95.34%
-768.78
-614.24%
-107.64
-134.70%
-45.86
Net Long Term Debt Issuance
197.69
+30.08%
151.98
-11.22%
171.19
-44.38%
307.82
Short Term Debt Issuance
—
—
0.00
-100.00%
160.00
Short Term Debt Payments
—
-9.50
0.00
+100.00%
-50.00
Net Short Term Debt Issuance
—
-9.50
0.00
+100.00%
-50.00
Net Common Stock Issuance
82.48
-45.18%
150.45
+9.92%
136.88
+1292.89%
9.83
Proceeds From Stock Option Exercised
0.00
-100.00%
4.92
-23.02%
6.39
0.00
Net Other Financing Charges
-9.34
+7.01%
-10.05
+23.56%
-13.14
-108.36%
157.27
Changes In Cash
116.42
+179.89%
41.59
+172.71%
-57.21
-216.79%
48.98
Effect Of Exchange Rate Changes
4.51
+440.71%
-1.32
-168.39%
1.94
+1813.27%
-0.11
Beginning Cash Position
51.43
+360.95%
11.16
-83.20%
66.43
+278.37%
17.56
End Cash Position
172.36
+235.15%
51.43
+360.95%
11.16
-83.20%
66.43
Free Cash Flow
-146.33
+50.20%
-293.84
+18.07%
-358.66
+0.76%
-361.39
Common Stock Issuance
82.48
-45.18%
150.45
+9.92%
136.88
+1292.89%
9.83
Earnings Losses From Equity Investments
-7.98
0.00
-100.00%
7.15
+176.18%
2.59
Interest Paid CFO
-58.95
-7.34%
-54.92
+4.07%
-57.25
-61.86%
-35.37
Interest Received CFO
2.39
-48.30%
4.62
+26.53%
3.65
+542.43%
0.57
Issuance Of Capital Stock
82.48
-45.18%
150.45
+9.92%
136.88
+1292.89%
9.83
Sale Of Business
5.95
-50.42%
12.00
0.00
0.00
Taxes Refund Paid
-0.78
+61.71%
-2.04
-50.44%
-1.35
-62.35%
-0.83
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category